1. Hirschler B. WHO wants transparency, market revamp for fairer drug pricing. 11 May 2017.
http://www.reuters.com/article/us-pharmaceuticals-pricing-idUSKBN1872PD
.
2. Culyer A. Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. December 2015 (CHE Research Paper 121).
3. Grocott R, Metcalfe S, Alexander P, Werner R. Assessing the value for money of pharmaceuticals in New Zealand: PHARMAC’s approach to cost-utility analysis. NZ Med J. 2013;126(1378):60–73.
4. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Threshold values for cost-effectiveness in health care. Brussels: Belgian Health Care Knowledge Centre (KCE); 2008.
5. Haycox A. Why cancer? Pharmacoeconomics. 2016;34(7):625–7.